{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T03:10:59Z","timestamp":1789528259664,"version":"build-2803163510"},"reference-count":62,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T00:00:00Z","timestamp":1733961600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Presse M\u00e9dicale"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.lpm.2024.104262","type":"journal-article","created":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T16:29:37Z","timestamp":1733761777000},"page":"104262","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Evolving strategies in the management of transplant-eligible patients with newly diagnosed multiple myeloma"],"prefix":"10.1016","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0131-8689","authenticated-orcid":false,"given":"Aurore","family":"Perrot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lpm.2024.104262_bib0001","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.lpm.2024.104262_bib0002","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S1470-2045(14)70282-7","article-title":"Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study","volume":"15","author":"Sant","year":"2014","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.lpm.2024.104262_bib0003","doi-asserted-by":"crossref","first-page":"e567","DOI":"10.1097\/HS9.0000000000000567","article-title":"Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow up","volume":"5","author":"Dimopoulos","year":"2021","journal-title":"Hemasphere"},{"issue":"5","key":"10.1016\/j.lpm.2024.104262_bib0004","first-page":"619","article-title":"Prolonged survival in a case of multiple myeloma treated with high dose melphalan","volume":"14","author":"Shibata","year":"1973","journal-title":"Rinsho Ketsueki"},{"issue":"8354","key":"10.1016\/j.lpm.2024.104262_bib0005","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/S0140-6736(83)90739-0","article-title":"High-dose intravenous melphalan for plasma-cell leukemia and myeloma","volume":"2","author":"McElwain","year":"1983","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2024.104262_bib0006","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1182\/blood.V79.5.1130.1130","article-title":"Intensive combined therapy for previously untreated aggressive myeloma","volume":"79","author":"Attal","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2024.104262_bib0007","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1182\/blood.V82.7.2005.2005","article-title":"High-dose chemoradiotherapy and autologous blood stem cell transplantation in multiple myeloma: results of a phase II trial involving 63 patients","volume":"82","author":"Fermand","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2024.104262_bib0008","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1200\/JCO.1994.12.4.759","article-title":"High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma","volume":"12","author":"Cunningham","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lpm.2024.104262_bib0009","first-page":"7","article-title":"Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group","volume":"95","author":"Lenhoff","year":"2000","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.lpm.2024.104262_bib0010","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","article-title":"A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in mutliple myeloma. Intergroupe Fran\u00e7ais du My\u00e9lome","volume":"335","author":"Attal","year":"1996","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.lpm.2024.104262_bib0011","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1182\/blood.V92.9.3131","article-title":"High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial","volume":"92","author":"Fermand","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2024.104262_bib0012","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","article-title":"High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma","volume":"348","author":"Child","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.lpm.2024.104262_bib0013","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1182\/blood-2004-02-0408","article-title":"Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial","volume":"104","author":"Palumbo","year":"2004","journal-title":"Blood"},{"issue":"36","key":"10.1016\/j.lpm.2024.104262_bib0014","doi-asserted-by":"crossref","first-page":"9227","DOI":"10.1200\/JCO.2005.03.0551","article-title":"High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe","volume":"23","author":"Fermand","year":"2005","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.lpm.2024.104262_bib0015","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1182\/blood-2005-03-1301","article-title":"High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA","volume":"106","author":"Blad\u00e9","year":"2005","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.lpm.2024.104262_bib0016","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1200\/JCO.2005.04.5807","article-title":"Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321","volume":"24","author":"Barlogie","year":"2006","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.lpm.2024.104262_bib0017","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2024.104262_bib0018","first-page":"39","article-title":"Early Versus late autologous stem cell transplant in newly diagnosed multiple myeloma: long-term follow-up analysis of the IFM","volume":"136","author":"Perrot","year":"2009","journal-title":"Trial. Blood 2020,"},{"issue":"2","key":"10.1016\/j.lpm.2024.104262_bib0019","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2204925","article-title":"Triplet therapy, transplantation, and maintenance until progression in myeloma","volume":"387","author":"Richardson","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.lpm.2024.104262_bib0020","doi-asserted-by":"crossref","first-page":"e456","DOI":"10.1016\/S2352-3026(20)30099-5","volume":"7","author":"Cavo","year":"2020","journal-title":"Lancet Haematol"},{"issue":"12","key":"10.1016\/j.lpm.2024.104262_bib0021","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S1470-2045(21)00535-0","volume":"22","author":"Gay","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.lpm.2024.104262_bib0022","series-title":"Presented at: 21st International Myeloma Society Annual Meeting","article-title":"Efficacy and safety of Isa-KRD induction before response-adapted consolidation in transplant eligible newly diagnosed multiple myeloma: an interim analysis of the IFM2020-02 MIDAS study","author":"Perrot","year":"2024"},{"issue":"Suppl","key":"10.1016\/j.lpm.2024.104262_bib0023","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/01.HS9.0000936220.68605.8b","article-title":"EMAGINE\/CARTITUDE-6: a randomized phase 3 study of DVRD followed by ciltacabtagene autoleucel versus DVRD followed by autologous stem cell transplant in transplant-eligible patients with newly diagnosed multiple myeloma","volume":"7","author":"Broijl","year":"2023","journal-title":"Hemasphere"},{"issue":"3","key":"10.1016\/j.lpm.2024.104262_bib0024","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1182\/blood.V99.3.731","volume":"99","author":"Moreau","year":"2002","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.lpm.2024.104262_bib0025","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1046\/j.1365-2141.2000.02093.x","article-title":"A combination of anti-interleukin 6 murine monoclonal antibody with dexamethasone and high-dose melphalan induces high complete response rates in advanced multiple myeloma","volume":"109","author":"Moreau","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.lpm.2024.104262_bib0026","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/bmt.2015.211","article-title":"A randomized study of melphalan 200 mg\/m2 vs 280 mg\/m2 as a preparative regimen for patients with multiple myeloma undergoing auto-SCT","volume":"51","author":"Bensinger","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.lpm.2024.104262_bib0027","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/j.1365-2141.2005.05641.x","article-title":"High-dose idarubicin, cyclophosphamide and melphalan as conditioning for autologous stem cell transplantation increases treatment-related mortality in patients with multiple myeloma: results of a randomised study","volume":"130","author":"Fenk","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.lpm.2024.104262_bib0028","doi-asserted-by":"crossref","first-page":"e266","DOI":"10.1016\/S2352-3026(19)30023-7","article-title":"Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial","volume":"6","author":"Bashir","year":"2019","journal-title":"Lancet Haematol"},{"issue":"18","key":"10.1016\/j.lpm.2024.104262_bib0029","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1182\/blood.2021014635","article-title":"Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study","volume":"139","author":"Roussel","year":"2022","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.lpm.2024.104262_bib0030","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/hon.2767","article-title":"Exploratory analysis of intensified conditioning as first line treatment for patients with high risk multiple myeloma","volume":"38","author":"Bommier","year":"2020","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.lpm.2024.104262_bib0031","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa032290","article-title":"Single versus double autologous stem cell transplantation for multiple myeloma","volume":"349","author":"Attal","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2024.104262_bib0032","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1200\/JCO.2006.10.2509","article-title":"Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: bologna 96 clinical study","volume":"25","author":"Cavo","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lpm.2024.104262_bib0033","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/bjh.13994","article-title":"Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long-term results from the phase III GMMG-HD2 trial","volume":"173","author":"Mai","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.lpm.2024.104262_bib0034","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1200\/JCO.18.00685","article-title":"Autologous transplantation, consolidation, and maintenance therapy in multiple myeloma: results of the BMT CTN 0702 trial","volume":"37","author":"Stadtmauer","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.lpm.2024.104262_bib0035","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1200\/JCO.23.01696","article-title":"Isatuximab, carfilzomib, lenalidomide, and dexamethasone for the treatment of high-risk newly diagnosed multiple myeloma","volume":"42","author":"Leypoldt","year":"2024","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.lpm.2024.104262_bib0036","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1182\/blood.2023023597","article-title":"Daratumumab, carfilzomib, lenalidomide and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma","volume":"143","author":"Touzeau","year":"2024","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.lpm.2024.104262_bib0037","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/S1470-2045(24)00282-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial","volume":"25","author":"Moreau","year":"2024","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.lpm.2024.104262_bib0038","doi-asserted-by":"crossref","first-page":"e-825-e837","DOI":"10.1016\/S2352-3026(23)00217-X","article-title":"Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial","volume":"10","author":"Voorhees","year":"2023","journal-title":"Lancet Haematol"},{"issue":"16","key":"10.1016\/j.lpm.2024.104262_bib0039","doi-asserted-by":"crossref","first-page":"suppl7502","DOI":"10.1200\/JCO.2024.42.16_suppl.7502","article-title":"Daratumumab + bortezomib\/lenalidomide\/dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma: analysis of minimal residual disease in the PERSEUS trial","volume":"42","author":"Rodr\u00edguez-Otero","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lpm.2024.104262_bib0040","doi-asserted-by":"crossref","first-page":"e810","DOI":"10.1016\/S2352-3026(22)00263-0","volume":"9","author":"Goldschmidt","year":"2022","journal-title":"Lancet Haematol"},{"issue":"suppl S1","key":"10.1016\/j.lpm.2024.104262_bib0041","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1182\/blood-2021-146040","article-title":"Daratumumab plus ixazomib, lenalidomide, and dexamethasone as extended induction and consolidation followed by lenalidomide maintenance in standard-risk transplant-eligible newly diagnosed multiple myeloma patients (IFM 2018-01)","volume":"138","author":"Perrot","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.lpm.2024.104262_bib0042","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1182\/blood-2023-177546","article-title":"Results of the phase III randomized iskia trial: isatuximab-carfilzomib-lenalidomide-dexamethasone vs carfilzomib-lenalidomide-dexamethasone as pre-transplant induction and post-transplant consolidation in newly diagnosed multiple myeloma patients","volume":"142","author":"Gay","year":"2023","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.lpm.2024.104262_bib0043","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1200\/JCO.22.02567","article-title":"Daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone as induction and extended consolidation improves outcome in ultra-high-risk multiple myeloma","volume":"41","author":"Kaiser","year":"2023","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.lpm.2024.104262_bib0044","doi-asserted-by":"crossref","first-page":"e890","DOI":"10.1016\/S2352-3026(23)00236-3","article-title":"Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial","volume":"10","author":"Costa","year":"2023","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.lpm.2024.104262_bib0045","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/bjh.17410","article-title":"Guidelines on the diagnosis, investigation and initial treatment of myeloma: a British Society for haematology\/UK myeloma forum guideline","volume":"193","author":"Sive","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.lpm.2024.104262_bib0046","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jtct.2022.03.019","article-title":"Astct clinical practice recommendations for transplantation and cellular therapies in multiple myeloma","volume":"28","author":"Dhakal","year":"2022","journal-title":"Transpl Cell Ther"},{"key":"10.1016\/j.lpm.2024.104262_bib0047","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am J Hematol"},{"issue":"10","key":"10.1016\/j.lpm.2024.104262_bib0048","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1016\/j.bbmt.2018.04.007","article-title":"Analysis of clinical factors and outcomes associated with nonuse of collected peripheral blood stem cells for autologous stem cell transplants in transplant-eligible patients with multiple myeloma","volume":"24","author":"Kansagra","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.lpm.2024.104262_bib0049","doi-asserted-by":"crossref","DOI":"10.1080\/07853890.2023.2281657","article-title":"Survival trends and prognostic factors of patients with newly diagnosed multiple myeloma accompanied with extramedullary disease","volume":"55","author":"Wang","year":"2023","journal-title":"Ann Med"},{"key":"10.1016\/j.lpm.2024.104262_bib0050","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41408-021-00587-0","article-title":"Primary plasma cell leukemia: consensus definition by the international Myeloma Working Group according to peripheral blood plasma cell percentage","volume":"11","author":"Fern\u00e1ndez de Larrea","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.lpm.2024.104262_bib0051","unstructured":"Avet-Loiseau H., Davies F.E., Samur M., et al. IMS\/IMWG consensus recommandations on the definition of high-risk multiple myeloma (Under review)."},{"issue":"15","key":"10.1016\/j.lpm.2024.104262_bib0052","article-title":"Long-term follow-up of BMT CTN 0702 (STaMINA) of postautologous hematopoietic cell transplantation (autoHCT) strategies in the upfront treatment of multiple myeloma (MM) [abstract]","volume":"38","author":"Hari","year":"2020","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.lpm.2024.104262_bib0053","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","article-title":"Lenalidomide maintenance after stem-cell transplantation for multiple myeloma","volume":"366","author":"Attal","year":"2012","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.lpm.2024.104262_bib0054","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","article-title":"Lenalidomide after stem-cell transplantation for multiple myeloma","volume":"366","author":"McCarthy","year":"2012","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.lpm.2024.104262_bib0055","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1402888","article-title":"Autologous transplantation and maintenance therapy in multiple myeloma","volume":"371","author":"Palumbo","year":"2014","journal-title":"N Engl J Med"},{"issue":"29","key":"10.1016\/j.lpm.2024.104262_bib0056","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","article-title":"Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis","volume":"35","author":"McCarthy","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.lpm.2024.104262_bib0057","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(18)30687-9","article-title":"Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial","volume":"20","author":"Jackson","year":"2019","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.lpm.2024.104262_bib0058","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.3324\/haematol.2020.247130","article-title":"Lenalidomide before and after autologous stem cell transplantation for transplant eligible patients of all ages in the randomized, phase III, Myeloma XI trial","volume":"106","author":"Jackson","year":"2021","journal-title":"Haematologica"},{"issue":"34","key":"10.1016\/j.lpm.2024.104262_bib0059","doi-asserted-by":"crossref","first-page":"4030","DOI":"10.1200\/JCO.20.02060","article-title":"Ixazomib as post induction maintenance for patients with newly diagnosed multiple myeloma not undergoing autologous stem cell transplantation: the phase III TOURMALINEMM4 trial","volume":"38","author":"Dimopoulos","year":"2020","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.lpm.2024.104262_bib0060","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1182\/blood-2011-09-379164","article-title":"Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p","volume":"119","author":"Neben","year":"2012","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.lpm.2024.104262_bib0061","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/leu.2013.335","article-title":"Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients","volume":"28","author":"Nooka","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.lpm.2024.104262_bib0062","article-title":"Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study","author":"Badros","year":"2024","journal-title":"Blood"}],"container-title":["La Presse M\u00e9dicale"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498224000411?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498224000411?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T23:46:23Z","timestamp":1741045583000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0755498224000411"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":62,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0755498224000411"],"URL":"https:\/\/doi.org\/10.1016\/j.lpm.2024.104262","relation":{},"ISSN":["0755-4982"],"issn-type":[{"value":"0755-4982","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evolving strategies in the management of transplant-eligible patients with newly diagnosed multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"La Presse M\u00e9dicale","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2024.104262","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"104262"}}